• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 39-53 of 68 results

1018 Exhibit: Ex 1018 US 5834495

Document IPR2021-01132, No. 1018-19 Exhibit - Ex 1018 US 5834495 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1023 Exhibit: Ex 1023 Pharmeuropa 2000

Document IPR2021-01132, No. 1023-24 Exhibit - Ex 1023 Pharmeuropa 2000 (P.T.A.B. Jun. 17, 2021)
List of certificates issued by the EDQM Official Announcement - Rapid Implementation on 01/01/2000 Magnesium stearate Isopropyl alcohol Products with risk of transmitting agents of animal spongiform encephalopathies Minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products (5.2.8) Replacement Production statements for monographs on TSE-risk products Aprotinin Aprotinin concentrated solution Calcium stearate Cholesterol Chymotrypsin Decyl oleate Diethylene glycol monopalmitostearate Erythromycin stearate Ethyl oleate Ethylene glycol monopalmitostearate Glycerol distearate Glycerol mono-oleates Glycerol monostearate 40-55 Hyaluronidase Insulin Macrogol stearate Macrogol stearyl ether Magnesium stearate Parnaparin sodium Propylene glycol monopalmitostearate Stearic acid Stearoyl macrogolglycerides Trypsin Vaccines for human use International Conferences Mycoplasma Testing the Potentialities & Roles of PCR Tests - 13-14 March 2000, Paris, France The Future Face of the European Pharmacopoeia Current Concerns in Pharmaceutical Analysis 9-10 October 2000, Lisbon, Portugal Tetanus Vaccines for Human Use 22-23 June 2000, Strasbourg, France
January 2000 General Information CD-ROM 2000 of the European Pharmacopoeia Press release: Conference in Berlin Conditions of sale of CRS List of CRS adopted in November 1999 Prepublication brochure (June 1999) List of texts published in the June 1999 prepublication brochure List of texts adopted in November 1999 Draft monographs for comment Arnica tincture Assay of human coagulation factor II (2.7...) Assay of human coagulation factor X (2.7...) Azaperone Bovine viral diarrhoea vaccine (inactivated) Canine adenovirus vaccine (live) Caraway oil Carbon dioxide Cetyl palmitate Dihydroergocristine mesilate Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed) 95 Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) Framycetin sulphate Gemfibrozil Greater celandine Heptaminol hydrochloride Human coagulation factor VII, freeze-dried Human plasma (pooled and treated for virus inactivation) Human prothrombin complex, freeze-dried Hymecromone Ibuprofen Iodinated (125I) human albumin injection Ioxaglic acid Java tea Levamisole Levamisole hydrochloride Lobeline hydrochloride Marsh mallow leaf Mesterolone Mint oil, dementholised Neomycin sulphate Netilmicin sulphate Nitrous oxide Oak bark Orphenadrine citrate Orphenadrine hydrochloride Phytosterol Pipemidic acid trihydrate Poloxamers Pravastatin sodium Rosemary oil Sage leaf (salvia officinalis) Semi-solid preparations for cutaneous application Sodium perborate trihydrate Star anise Thyme Wild pansy (flowering aerial parts) Zinc stearate © PHARMEUROPA Vol.
The previous edition contained translations in sixteen European languages : Croatian, Danish, Dutch, English, Finnish, French, German, Greek, Italian, Norwegian, Portuguese, Slovak, Slovenian, Spanish, Swedish and Turkish).
Information and orders: Council of Europe European Department for the Quality of Medicines (EDQM) BP 907 - F67029 Strasbourg Cedex 1 tel.
Readers of Pharmeuropa are asked to inform EDQM of their opinion on the need for a test and limit in the light of their experience with mesilate salts.
cite Cite Document

1024 Exhibit: Ex 1024 Aakeroy

Document IPR2021-01132, No. 1024-25 Exhibit - Ex 1024 Aakeroy (P.T.A.B. Jun. 17, 2021)
Potential applications for the design of novel materials with predictable structural features and properties can be found in almost every commercial and academic area concerned with macroscopic structure-property considerations, e.g. non- t Permanent address: University of Sussex, School of Chemistry and Molecular Sciences, Falmer, Brighton, UK BN 1 9QJ.
However, since the existing graph-set language is not always adequate for examining multi-dimensional aggregates with a high hydrogen-bond density (a consequence of the inherent difficulties with translating 3D information into scalar quanti- ties), an additional descriptor,$ based upon the terminology of Etter et al., has been utilized as a means of specifically representing 2D hydrogen-bonded networks.
Most patterns in organic molecular solids can be adequately described in terms of four principal motifs; chains (C), dimers (D), rings ( R ) and intramol- ecular hydrogen bonds (S).V Although this notation may not $ The 2D descriptor utilized in this paper is employed as a means of facilitating a comparison and analysis of specific aggregate-types.
Although it is impossible to predict, a priori, the exact arrangement of the cations within this salt, their spatial freedom' has been severely restricted by the presence and geometry of the anionic sheets, thereby locking them into the structural framework in the anticipated fashion.
The relevant crystallographic data were the transferred to a Macintosh IIfx and a Silicon Graphics Workstation where software from CAChe Tektronix, Molecular Simulation Inc. (Cerius 3.2 and Quanta 3.3) and Biosym (Insight/Discover 2.10) was employed in the analysis of the patterns generated by the hydrogen bonds within these structures.
cite Cite Document

1014 Exhibit: Ex 1014 Morris

Document IPR2021-01132, No. 1014-15 Exhibit - Ex 1014 Morris (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1007 Exhibit: Ex 1007 550 PH Part 1 of 2

Document IPR2021-01132, No. 1007-7 Exhibit - Ex 1007 550 PH Part 1 of 2 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1001 Exhibit: Ex 1001 927 patent

Document IPR2021-01132, No. 1001 Exhibit - Ex 1001 927 patent (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1005 Exhibit: Ex 1005 Coe

Document IPR2021-01132, No. 1005 Exhibit - Ex 1005 Coe (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1023 Exhibit: Ex 1023 Pharmeuropa 2000

Document IPR2021-01132, No. 1023 Exhibit - Ex 1023 Pharmeuropa 2000 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1008 Exhibit: Ex 1008 CA 2467490

Document IPR2021-01132, No. 1008 Exhibit - Ex 1008 CA 2467490 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1021 Exhibit: Ex 1021 US 6794388

Document IPR2021-01132, No. 1021 Exhibit - Ex 1021 US 6794388 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1024 Exhibit: Ex 1024 Aakeroy

Document IPR2021-01132, No. 1024 Exhibit - Ex 1024 Aakeroy (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1014 Exhibit: Ex 1014 Morris

Document IPR2021-01132, No. 1014 Exhibit - Ex 1014 Morris (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1006 Exhibit: Ex 1006 US 6410550

Document IPR2021-01132, No. 1006 Exhibit - Ex 1006 US 6410550 (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1003 Exhibit: Ex 1003 Gould CV

Document IPR2021-01132, No. 1003 Exhibit - Ex 1003 Gould CV (P.T.A.B. Jun. 17, 2021)

cite Cite Document

1010 Exhibit: Ex 1010 Gould

Document IPR2021-01132, No. 1010 Exhibit - Ex 1010 Gould (P.T.A.B. Jun. 17, 2021)

cite Cite Document
<< 1 2 3 4 5 >>